Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Schematy leczenia wysiękowej postaci AMD – wady i zalety

100%
Święch-Zubilewicz A., Dolar-Szczasny J.
OphthaTherapy
|
2016
|
vol. 3
|
issue 1
32-36
EN
Anti-VEGF treatment is a gold standard in exudative AMD. Three drugs are currently used: ranibizumab (Lucentis), aflibercept (Eylea) and off-label bevacizumab (Avastin). Different treatment regimen are used: fixed scheduled treatment, pro re nata and treat and extend.
PL
Terapia anty-VEGF jest obecnie standardem w przypadku wysiękowej postaci AMD. Stosowane leki to: ranibizumab (Lucentis), aflibercept (Eylea) oraz bewacyzumab (Avastin). Ten ostatni w okulistyce podawany jest off-label. Schematy leczenia są różne. Leki można stosować według sztywnego schematu, w zależności od potrzeby (pro re nata) lub w schemacie treat and extend.
2
Publication available in full text mode
Content available

Jak leczymy i dokąd zmierzamy w terapii AMD?

81%
Święch-Zubilewicz A., Dolar-Szczasny J., Mackiewicz J.
OphthaTherapy
|
2014
|
vol. 1
|
issue 1
4-10
EN
The number of patients with age-related macular degeneration in population over 50 increases constantly, however the exact etiology of that pathology is still not well known. Previously used wet AMD treatment methods such as radiotherapy, laser therapy or photodynamic therapy were not successful. Now the gold standard for wet AMD treatment is the use of intravitreally administered anti-VEGF antagonists such as ranibizumab, aflibercept or off-label bevacizumab. However these medications are directed against the symptoms and not the cause of described pathology. Probable multifactorial etiology of AMD needs further improvement in therapy of that disease. New immunomodulators, neuroprotectors, antioxidants as well as gene therapy is currently under investigations to improve AMD treatment.
PL
Zwyrodnienie plamki żółtej związane z wiekiem dotyczy coraz większej liczby chorych po 50. r.ż., jednakże etiologia tego schorzenia nie została dotychczas dokładnie poznana. Terapie stosowane w wysiękowej postaci AMD, takie jak radioterapia, laseroterapia czy fototerapia dynamiczna, okazały się nieskuteczne i obecnie standardem w leczeniu tego schorzenia jest podawanie doszklistkowe leków z grupy antagonistów VEGF, takich jak ranibizumab, aflibercept czy off-label bewacyzumab. Preparaty powyższe nie likwidują jednak przyczyny AMD, ale mają głównie działanie objawowe. Przypuszczalna wieloczynnikowa etiologia AMD wskazuje na konieczność poszukiwania nowych metod leczenia tego schorzenia. W związku z tym w fazie badań są leki wpływające na układ immunologiczny, substancje neuroprotekcyjne, antyoksydacyjne, terapie genowe
3
Content available remote

Innovation in retinal diseases – ultra-widefield imaging

81%
Dolar-Szczasny J., Święch-Zubilewicz A., Mackiewicz J.
Polish Journal of Public Health
|
2015
|
vol. 125
|
issue 1
14-16
EN
The understanding of retinal disease has evolved rapidly with a growing number of clinical evidence supplied by ultrawidefield retinal imaging. Optos 200Tx ultra-widefield retinal imaging system uses a scanning laser ophthalmoscope, as well as an ellipsoid mirror. This creates a possibility of making a virtual focal point inside the eye and, in turn, enables the system to simultaneously make a single capture of the central retina and periphery. This system offers multimodal ultra-widefield imaging, including color photographs, fundus autofluorescence images, red-free images and fluorescein angiography (FA), allowing visualization of the retinal circulation. For color photographs, green and red lasers are used simultaneously to allow visualization of retinal substructures from the sensory retina and retinal pigment epithelium to the choroid. In our clinic ultra-widefield fluorescein angiography has became an elegant diagnostic imaging modality that has improved our ability to diagnose and plan treatment strategies. In the future widefield imaging will probably be coupled with OCT (optical coherence tomography) option to better evaluate retinal pathologies in the periphery.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.